Johnson Fistel Investigates Potential Claims Against Alto Neuroscience, Inc. Officers and Directors

Strategic Insights -

Johnson Fistel, PLLP is investigating potential claims on behalf of Alto Neuroscience, Inc. (NYSE: ANRO) shareholders against the company's officers and directors who may have breached their fiduciary duties. A federal securities fraud class action complaint alleges that Alto Neuroscience made materially false and misleading statements about its business, operations, and prospects. The complaint specifically claims that the company's officers led investors to believe that ALTO-100, a treatment for Major Depressive Disorder (MDD), was more effective than it actually was. This allegedly led to the company's public statements being materially false and misleading at all relevant times.

Key Takeaways:

  • Johnson Fistel is investigating potential claims on behalf of Alto Neuroscience, Inc. shareholders against the company's officers and directors.
  • A federal securities fraud class action complaint alleges that Alto Neuroscience made materially false and misleading statements about its business, operations, and prospects.
  • The complaint claims that the company's officers led investors to believe that ALTO-100 was more effective than it actually was.
  • The company's public statements were allegedly materially false and misleading at all relevant times.
  • Shareholders may be eligible to seek corporate reforms, the return of funds to the company, and a court-approved incentive award at no cost to them.
  • Johnson Fistel is a nationally recognized shareholder rights law firm representing individual and institutional investors in shareholder derivative and securities class action lawsuits.

Statistics:

  • The complaint specifically claims that the company's officers led investors to believe that ALTO-100 was 100% more effective than it actually was.
  • Alto Neuroscience, Inc. (NYSE: ANRO) is a publicly traded company listed on the New York Stock Exchange.
  • The company's officers and directors may have breached their fiduciary duties to the company.
  • Johnson Fistel has been involved in numerous shareholder derivative and securities class action lawsuits, representing individual and institutional investors.

Sources:

  • GlobeNewswire (Aug. 27, 2025) - "Johnson Fistel Investigates Potential Claims on Behalf of Alto Neuroscience, Inc. (NYSE: ANRO) Shareholders"
  • Johnson Fistel, PLLP official website - "About Johnson Fistel, PLLP"
  • COMTEX_468345646/2010/2025-08-27T14:17:23